The Behavioral Wire Briefing — a weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next across pharma, psychedelics, cannabis, digital health, regulation, markets, and research.
Psilocybin, MDMA, ibogaine, ketamine. Trials, regulation, religious exemptions, state programs.
The agreement itself is a coordination document, not a funding commitment or an access pathway. What makes it significant is what it arrived alongside: FDA's final clinical guidance, a September public hearing, and separate ibogaine-specific funding moves from NIDA and ARPA-H, all announced the same day.
Three years after its first draft, FDA has issued final guidance on how to design a psychedelic clinical trial. It does not loosen the bar. It specifies, in granular and sometimes uncomfortable detail, exactly what the agency now expects on blinding, cardiac safety, durability, and drug interactions, the precise questions that have sunk or slowed nearly every program this desk has covered.
The Massachusetts House passed a five-year, three-clinic psilocybin and ibogaine pilot program, tucked into a $561 million economic development bill. Where the state's 2024 legalization ballot measure failed at the polls, this version is narrow, clinical, state-run, and built around a fixed pilot rather than broad personal access, a different model entirely, still needing the Senate and the Governor before it is law.
Psilocybin's clinical trials have repeatedly shown a durable increase in openness after a single supervised dose. A large naturalistic study of German university students set out to see whether that effect shows up in ordinary first-time use. After the statistics were done properly, it mostly disappeared, and what was left wasn't specific to psychedelics at all.
Imperial College London's Centre for Psychedelic Research has published a small, long-running pilot of psilocybin therapy in women with severe, treatment-resistant anorexia nervosa. Eating-disorder symptom scores improved and held for a year in an indication with almost nothing that works. The design, open-label, uncontrolled, in 21 people, sets a hard ceiling on what can be concluded from it.
Compass Pathways' Phase 3 COMP006 trial shows 39 percent of patients on the 25 mg dose maintained response through six months. That number is real. What "maintained" actually means, once you read past the topline, is a post hoc, completers-based analysis in which most patients received an additional intervention along the way. Both things are true at once, and the gap between them is the story.
While psychedelic and cannabinoid drug developers chase headlines, a Texas contract manufacturer has spent the past year and a half filing DEA registration after DEA registration to handle their raw materials, LSD, ibogaine, mescaline, marijuana extract, and more. It is the least glamorous, most necessary layer of the industry, and it is expanding fast.
Canada built two successive federal pathways to get psilocybin and MDMA to patients outside clinical trials. The second one fixed the supply chain the first one lacked, and in doing so made access harder to get, not easier. As U.S. states write their own trigger laws and access frameworks, that trade-off is the one worth studying before it repeats.
A Copenhagen research program is mapping the direct dose-occupancy relationship between LSD and the serotonin 2A receptor in living human brains, the pharmacodynamic binding data that clinical psychedelic trials have mostly assumed rather than measured. With interim results already published and the full program running through 2027, it is the empirical foundation the dosing decisions in Definium's lysergide program could stand to be built on.
Compass Pathways' crystalline-polymorph psilocybin patent has reached granted status as COMP360 moves into rolling FDA submission and the regulatory path clears. Psilocybin itself cannot be patented, so the entire pharmaceutical-psilocybin model rests on owning the exact crystalline form, and patent lawyers still disagree on how much that actually blocks.
Psilocybin for smoking cessation produced some of the most striking pilot results in psychedelic medicine, up to 80 percent abstinence in the first tiny study. It is now in a NIDA-funded multi-site Phase 2, which is both a marker of federal money entering psychedelic-addiction research and the test of whether those eye-popping early effects survive rigor.
A new West Virginia statute is being read as a state prescription pathway for psilocybin that runs ahead of federal scheduling. It is the opposite: a contingent trigger that activates only if the FDA approves and the DEA reschedules a crystalline-polymorph psilocybin first. That structure, and the polymorph language, quietly pick a side in how psilocybin access gets built.
The commercial hope in psychedelics is a drug that keeps the antidepressant effect and drops the hallucination by being selective for the 5-HT2A receptor. The preclinical evidence points the other way: psilocybin's benefit appears to depend on more than 5-HT2A, and if the missing piece is a receptor like 5-HT2B, the one developers normally design around for cardiac safety, two of the field's bets get harder at once.
Definium Therapeutics, the company formerly known as MindMed, reported positive topline Phase 3 results for an orally dissolving form of LSD in major depression. With a second MDD trial, two Phase 3 anxiety trials, and a PTSD study to come, lysergide is now arguably the most advanced classic psychedelic in registrational development. The trial design takes direct aim at the field's biggest methodological problem.
MDMA-assisted therapy is moving beyond PTSD into eating disorders, on the logic that trauma underlies many of these conditions. It is a real research direction, but not a first, and the evidence so far is a secondary analysis and a few early trials. That is the right place to set expectations.
Psilocybin's strongest cancer evidence is in anxiety and depression. A Roswell Park trial extends it to chronic cancer pain and opioid reduction, part of a broader psychedelics-for-pain wave. Treating pain is a different and less-supported claim than treating distress, and the distinction is the whole story.
MDMA cannot be patented; it is a 1912 molecule. So the commercial action has moved to engineered analogues, especially short-acting ones that would shrink the eight-hour session that makes MDMA therapy hard to scale. After the 2024 FDA rejection, the filings, not the trials, are where the next MDMA strategy is taking shape.
On the same day, the New England Journal of Medicine ran one piece on the collision between state-authorized psychedelic programs and federal Schedule I status, and another on informed consent and shared decision-making in psychedelic care. The pairing, and the venue, are the signal: the field's unresolved questions are now jurisdictional and ethical, not pharmacological.
A Yale Phase 1 is testing DMT in major depression with EEG endpoints, part of a psychedelic quietly catching up to psilocybin and MDMA. Its short duration is the structural answer to the session-length problem the rest of the field is spending money to engineer. Whether brevity is enough is the open question.
A new paper quantifies MDMA's concentration-dependent inhibition of CYP2D6, the enzyme that metabolizes several antidepressants common in the PTSD population MDMA therapy is meant to treat. The pharmacokinetic interaction is real, though it is not the only reason concomitant antidepressants get managed.
Compass's pivotal evidence spans North America and Europe and points toward an FDA filing. Australia skipped that route in 2023, letting psychiatrists prescribe psilocybin with no completed pivotal trial. The global path to psychedelic access is fragmenting into models that do not agree on what evidence is required first.
HLP003, Helus Pharma's deuterated psilocin analog engineered for a shorter trip, is now months from its first Phase 3 readout in major depression. It does not differ from Compass on biology. It differs on session length, dosing, and the breadth of the population it targets.
A new PNAS paper reports that psychedelics scramble hierarchical cortical propagation in the default mode network across both humans and mice. The cross-species match strengthens the case that this disruption is a real circuit mechanism. It says nothing yet about whether the disruption helps anyone.
A five-year NIDA award sends federal researchers into Oregon's legal psilocybin program to track safety and substance-use outcomes in thousands of real clients. It is the first dataset built from psychedelic use outside controlled-trial conditions, and that is the point.
Compass hit both pivotal trials, has a rolling NDA underway, and holds a priority voucher that could compress review to one or two months. The regulatory path is now the fast part. The durability and effect-size data are the part still being written.
A map of the surviving programs after the August 2024 MDMA rejection and the April 2026 voucher decisions. The field is narrower than press coverage suggests, and the survivors are concentrated in a small number of well-funded sponsors with overlapping bets on the same handful of molecules.
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| COMP360 psilocybin Treatment-resistant depression | Compass Pathways | Phase 3 | Phase 3 complete; rolling NDA underway |
| HLP003 (deuterated psilocin) Major depressive disorder | Helus Pharma (formerly Cybin) | Phase 3 | Breakthrough designation; Phase 3 APPROACH topline expected 2H 2026 |
| DT120 (lysergide ODT) Major depressive disorder | Definium Therapeutics (formerly MindMed) | Phase 3 | Phase 3 positive; second trial enrolling |
| DT120 (lysergide ODT) Generalized anxiety disorder | Definium Therapeutics (formerly MindMed) | Phase 3 | Breakthrough designation |
| BPL-003 (intranasal mebufotenin) Treatment-resistant depression | AtaiBeckley | Phase 2 | Topline positive |